89 related articles for article (PubMed ID: 33539601)
1. In Regard to "A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)".
Ricci AD; Rizzo A; Brandi G
Oncologist; 2021 May; 26(5):e902. PubMed ID: 33539601
[TBL] [Abstract][Full Text] [Related]
2. A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08).
McNamara MG; Bridgewater J; Palmer DH; Faluyi O; Wasan H; Patel A; Ryder WD; Barber S; Gnanaranjan C; Ghazaly E; Evans TRJ; Valle JW
Oncologist; 2021 Apr; 26(4):e669-e678. PubMed ID: 33210382
[TBL] [Abstract][Full Text] [Related]
3. NUC-1031 in biliary tract cancer: from bench to bedside and back?
Boyd LNC; Peters GJ; Kazemier G; Giovannetti E
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1011-1014. PubMed ID: 32476108
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM
Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer.
Bridgewater J; Lopes A; Wasan H; Malka D; Jensen L; Okusaka T; Knox J; Wagner D; Cunningham D; Shannon J; Goldstein D; Moehler M; Bekaii-Saab T; McNamara MG; Valle JW
Ann Oncol; 2016 Jan; 27(1):134-40. PubMed ID: 26483051
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study.
Blagden SP; Rizzuto I; Suppiah P; O'Shea D; Patel M; Spiers L; Sukumaran A; Bharwani N; Rockall A; Gabra H; El-Bahrawy M; Wasan H; Leonard R; Habib N; Ghazaly E
Br J Cancer; 2018 Oct; 119(7):815-822. PubMed ID: 30206366
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer.
Kim TW; Chang HM; Kang HJ; Lee JR; Ryu MH; Ahn JH; Kim JH; Lee JS; Kang YK
Ann Oncol; 2003 Jul; 14(7):1115-20. PubMed ID: 12853355
[TBL] [Abstract][Full Text] [Related]
8. New developments in systemic therapy for advanced biliary tract cancer.
Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
[TBL] [Abstract][Full Text] [Related]
9. Surgical treatment for non-dilated biliary tract with pancreaticobiliary maljunction should include excision of the extrahepatic bile duct.
Hara H; Morita S; Ishibashi T; Sako S; Dohi T; Iwamoto M; Tanigawa N
Hepatogastroenterology; 2001; 48(40):984-7. PubMed ID: 11490854
[TBL] [Abstract][Full Text] [Related]
10. Combined chemotherapy of irinotecan and low-dose cisplatin (I/low-P) against metastatic biliary tract cancer.
Sugita H; Hirota M; Ichihara A; Furuhashi S; Kihara S; Shimada S
J Hepatobiliary Pancreat Surg; 2006; 13(5):463-7. PubMed ID: 17013724
[TBL] [Abstract][Full Text] [Related]
11. Biliary tract cancer treatment: results from the Biliary Tract Cancer Statistics Registry in Japan.
Nagakawa T; Kayahara M; Ikeda S; Futakawa S; Kakita A; Kawarada H; Matsuno M; Takada T; Takasaki K; Tanimura H; Tashiro S; Yamaoka Y
J Hepatobiliary Pancreat Surg; 2002; 9(5):569-75. PubMed ID: 12541042
[TBL] [Abstract][Full Text] [Related]
12. Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials.
Lamarca A; Ross P; Wasan HS; Hubner RA; McNamara MG; Lopes A; Manoharan P; Palmer D; Bridgewater J; Valle JW
J Natl Cancer Inst; 2020 Feb; 112(2):200-210. PubMed ID: 31077311
[TBL] [Abstract][Full Text] [Related]
13. [A Case of Distal Bile Duct Cancer Occurring 38 Years after Cyst-to-Duct Anastomosis for a Congenital Biliary Dilatation].
Okumura Y; Asaoka T; Eguchi H; Iwagami Y; Yamada D; Noda T; Wada H; Kawamoto K; Goto K; Mori M; Doki Y
Gan To Kagaku Ryoho; 2016 Nov; 43(12):2095-2097. PubMed ID: 28133233
[TBL] [Abstract][Full Text] [Related]
14. Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer.
Jung JH; Lee HS; Jo JH; Cho IR; Chung MJ; Bang S; Park SW; Song SY; Park JY
Chemotherapy; 2017; 62(6):361-366. PubMed ID: 28848173
[TBL] [Abstract][Full Text] [Related]
15. Phenylethyl isothiocyanate reverses cisplatin resistance in biliary tract cancer cells via glutathionylation-dependent degradation of Mcl-1.
Li Q; Zhan M; Chen W; Zhao B; Yang K; Yang J; Yi J; Huang Q; Mohan M; Hou Z; Wang J
Oncotarget; 2016 Mar; 7(9):10271-82. PubMed ID: 26848531
[TBL] [Abstract][Full Text] [Related]
16. Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).
Arkenau HT; Martin-Liberal J; Calvo E; Penel N; Krebs MG; Herbst RS; Walgren RA; Widau RC; Mi G; Jin J; Ferry D; Chau I
Oncologist; 2018 Dec; 23(12):1407-e136. PubMed ID: 29853658
[TBL] [Abstract][Full Text] [Related]
17. [Adjuvant chemical treatment for bile duct cancer].
Itoh Y
Nihon Rinsho; 2006 Jan; 64 Suppl 1():539-42. PubMed ID: 16457321
[No Abstract] [Full Text] [Related]
18. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
[TBL] [Abstract][Full Text] [Related]
19. Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer.
Neuzillet C; Casadei-Gardini A; Brieau B; Vivaldi C; Brandi G; Tougeron D; Filippi R; Vienot A; Silvestris N; Pointet AL; Lonardi S; Rousseau B; Scartozzi M; Dahan L; Aprile G; Le Sourd S; Evesque L; Meurisse A; Lièvre A; Vernerey D; ;
Int J Cancer; 2020 Dec; 147(11):3177-3188. PubMed ID: 32525595
[TBL] [Abstract][Full Text] [Related]
20. Thermo-chemo-radiotherapy for advanced bile duct carcinoma.
Kamisawa T; Tu Y; Egawa N; Karasawa K; Matsuda T; Tsuruta K; Okamoto A
World J Gastroenterol; 2005 Jul; 11(27):4206-9. PubMed ID: 16015690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
